Applications of Microparticles: A Review
Article Sidebar
-
Microspheres, Target Site, Controlled Release, Novel Drug Delivery
Abstract
The small size and effective carrier capacity of microspheres make them a crucial component of novel drug delivery systems. With a particle size range of 1-1000 μm, microspheres are distinctively free-flowing powders made of synthetic polymers or proteins. The range of microsphere production methods provides several chances to regulate drug delivery processes and improve the therapeutic potency of certain medications. There are numerous techniques for delivering therapeutic medicines to target areas over time. One such technique is to employ microspheres, also known as microparticles, as medication carriers. When adjusted and kept at the correct concentrations at the location of interest, it provides a dependable method of delivering medications selectively to target areas. In addition to their capabilities for prolonged release, microspheres have received a lot of attention.
Full text article
References
M K Das, A B Ahmed, and D Saha. Microsphere a drug delivery system: A review. Int J Curr Pharm Res, 11(4):34–41, 2019.
P Parida, S C Mishra, S Sahoo, A Behera, and B P Nayak. Development and characterization of ethylcellulose based microsphere for sustained release of nifedipine. Journal of pharmaceutical analysis, 6(5):341–344, 2016.
K J Beyatricks. Recent trends in microsphere drug delivery system and its therapeutic applications - A Review. Crit. Rev. Pharm. Sci, 2(1):1–14, 2013.
M A Atkinson and G S Eisenbarth. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. The Lancet, 358(9277):221–229, 2001.
H E Thomas, R Darwiche, J A Corbett, and T W Kay. Interleukin-1 plus γ-interferon-induced pancreatic β-cell dysfunction is mediated by β-cell nitric oxide production. Diabetes, 51(2):311–316, 2002.
M Arnush, M R Heitmeier, A L Scarim, M H Marino, P T Manning, and J A Corbett. IL-1 produced and released endogenously within human islets inhibits beta cell function. The Journal of clinical investigation, 102(3):516–526, 1998.
M Abdul-Rasoul, H Habib, and M Al-Khouly. ‘The honeymoon phase’ in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatric diabetes, 7(2):101–107, 2006.
P F Bougnères, P Landais, C Boisson, J C Carel, N Frament, C Boitard, and J F Bach. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes, 39(10):1264–1272, 1990.
R Lipton, R E Laporte, D J Becker, J S Dorman, T J Orchard, J Atchison, and A L Drash. Cyclosporin therapy for prevention and cure of IDDM: epidemiological perspective of benefits and risks. Diabetes care, 13(7):776–784, 1990.
L Chatenoud. CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications. Current opinion in immunology, 17(6):632–637, 2005.
K C Herold, S E Gitelman, U Masharani, W Hagopian, B Bisikirska, D Donaldson, and J A Bluestone. A single course of anti-CD3 monoclonal antibody hOKT3γ1 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes, 54(6):1763–1769, 2005.
N Babaya, M Nakayama, and G S Eisenbarth. The stages of type 1A diabetes. Annals of the New York Academy of Sciences, 1051(1):194–204, 2005.
R S Allan, J Waithman, S Bedoui, C M Jones, J A Villadangos, Y Zhan, and F R Carbone. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity, 25(1):153–162, 2006.
F R Carbone, G T Belz, and W R Heath. Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends in immunology, 25(12):655–658, 2004.
C Scheinecker, R Mchugh, E M Shevach, and R N Germain. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. The Journal of experimental medicine, 196(8):1079–1090, 2002.
K R Mccurry, B L Colvin, A F Zahorchak, and A W Thomson. Regulatory dendritic cell therapy in organ ransplantation. Transplant international, 19(7):525–538, 2006.
J Machen, J O Harnaha, R Lakomy, A Styche, M Trucco, and N Giannoukakis. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. The Journal of Immunology, 173(7):4331–4341, 2004.
M Yoshida and J E Babensee. Molecular aspects of microparticle phagocytosis by dendritic cells. Journal of Biomaterials Science, 17(8):893–907, 2006.
V H L Lee and J R Robinson. Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits. Journal of pharmaceutical sciences, 68(6):673–684, 1979.
A Zimmer and J Kreuter. Microspheres and nanoparticles used in ocular delivery systems. Advanced drug delivery reviews, 16:61–73, 1995.
J Kang-Mieler and E Brey. Biodegradable microsphere hydrogel ocular drug delivery system, 2017. United States Patent No. US 2017/0087248 A1.
L Pereswetoff-Morath. Microspheres as nasal drug delivery systems. Advanced Drug Delivery Reviews, 29(1-2):185–194, 1998.
P Modi. Vaccine Delivery System For Immunization, Using Biodegradable Polymer Microspheres 76, 1996. USOO5569468A.
H K Lee, J H Park, N S Choi, M J Kim, and S H Kim. U.S. Patent No. 5,753,234. Washington, DC: U.S. Patent and Trademark Office, 1998.
Hamilton. Drugs, vaccines and hormones in polylactide coated microspheres, 2019. EP0744940B1.
P W S Andrew Lennard Lewis and Yiqing Tang. Microspheres for treatment of brain tumors. United States Patent No. US 8,691,791 B2.
U O Häfeli. Magnetically modulated therapeutic systems. International journal of pharmaceutics, 277(1-2):19–24, 2004.
M S Rajput and P Agrawal. Microspheres in cancer therapy. Indian Journal of Cancer, 47(4):458–468, 2010.
P G Rose, B N Bundy, E B Watkins, J T Thigpen, G Deppe, M A Maiman, and S Insalaco. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New England Journal of Medicine, 340(15):1144–1153, 1999.
B Brando, D Barnett, G Janossy, F Mandy, B Autran, and G Rothe. Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. Cytometry, 42(6):327–346, 2000.
Authors
Copyright (c) 2023 International Journal of Research in Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Article Details
